The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes
Abstract
Aims: The alpha-glucosidase inhibitor acarbose is believed to reduce plasma glucose by delaying hydrolysis of carbohydrates. Acarbose-induced transfer of carbohydrates to the distal parts of the intestine increases circulating glucagon-like peptide 1 (GLP-1). Using the GLP-1 receptor antagonist exendin(9–39)NH 2 , we investigated the effect of acarbose-induced GLP-1 secretion on postprandial glucose metabolism in patients with type 2 diabetes. Methods: In a double-blinded, placebo-controlled, randomized, crossover study, 15 participants with metformin-treated type 2 diabetes (age: 57–85 years, HbA1c: 40–74 mmol/mol) were subjected to two 14-day treatment periods with acarbose or placebo, respectively, separated by a 6-week wash-out period. At the end of each period, two randomized 4-h liquid mixed meal tests with concomitant infusion of exendin(9–39)NH 2 and saline, respectively, were performed. Results: Compared to placebo, acarbose increased postprandial GLP-1 concentrations and decreased postprandial glucose. We observed no absolute difference in the exendin(9–39)NH 2 -induced increase in postprandial glucose excursions between placebo and acarbose periods, but relatively, postprandial glucose was increased by 119 ± 116% (mean ± s.d. ) during exendin(9–39)NH 2 infusion in the acarbose period vs a 39 ± 27% increase during the placebo period ( P = 0.0163). Conclusions: We confirm that acarbose treatment stimulates postprandial GLP-1 secretion in patients with type 2 diabetes. Using exendin(9–39)NH 2 , we did not see an impact of acarbose-induced GLP-1 secretion on absolute measures of postprandial glucose tolerance, but relatively, the effect of exendin(9–39)NH 2 was most pronounced during acarbose treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a -Glucosidase inhibitors improve glycemic control by reducing postprandial glycemic excursions and glycemic variability and may provide speci fi c benefi ts in cultures and settings with high carbohydrate consumption or reactive hypoglycemia (221,222).”
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationAccurate measurement of cholecystokinin in plasma
Rehfeld, J. F. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.5.991 · Cited by 320
Self-citationDetermination of gastrin in serum. An evaluation of the reliability of a radioimmunoassay.
STADIL, F., & Rehfeld, J. F. (1973) · PubMed · Cited by 301
Self-citationJørgensen, N. B., Dirksen, C., Bojsen-Møller, K. N., Jacobsen, S. H., Worm, D., Hansen, D. L., Kristiansen, V. B., Naver, L., Madsbad, S., & Holst, J. J. (2013) · Diabetes · doi:10.2337/db13-0022 · Cited by 288
Self-citationde Heer, J., Rasmussen, C., Coy, D. H., & Holst, J. J. (2008) · Diabetologia · doi:10.1007/s00125-008-1149-y · Cited by 239
Self-citationDetermination of Gastrin in Serum: An Evaluation of the Reliability of a Radioimmunoassay
Stadil, F., & Rehfeld, J. F. (1973) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.1973.12096677 · Cited by 197
Self-citationSvane, M. S., Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Nielsen, S., Kristiansen, V. B., Toräng, S., Wewer Albrechtsen, N. J., Rehfeld, J. F., Hartmann, B., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.121 · Cited by 185
Self-citationType 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications
Anwar, A., Walker, J. D., & Frier, B. M. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199802)15:2<129::aid-dia535>3.0.co;2-2 · Cited by 161
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
“a-Glucosidase inhibitors improve glycemic control by reducing postprandial glycemic excursions and glycemic variability and may provide specific benefits in cultures and settings with high carbohydrate consumption or reactive hypoglycemia (221,222).”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
“Less commonly used glucose-lowering medications Alphaglucosidase inhibitors improve glycaemic control by reducing postprandial glycaemic excursions and glycaemic variability and may provide specific benefits in cultures and settings with high carbohydrate consumption or reactive hypoglycaemia [221, 222].”
Signaling pathways and intervention for therapy of type 2 diabetes mellitus
Cao, R. Y., Tian, H., Zhang, Y., Liu, G., Xu, H., Rao, G., Tian, Y., & Fu, X. (2023) · MedComm · doi:10.1002/mco2.283 · Cited by 107
Molecular Mechanism for the α-Glucosidase Inhibitory Effect of Wheat Germ Peptides
Liu, W., Li, H., Wen, Y., Liu, Y., Wang, J., & Sun, B. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c06098 · Cited by 79
Mashayekhi, M., Nian, H., Mayfield, D., Devin, J. K., Gamboa, J. L., Yu, C., Silver, H. J., Niswender, K. D., Luther, J. M., & Brown, N. J. (2023) · Diabetes · doi:10.2337/db23-0356 · Cited by 83
Metadata
- Authors
- Dalsgaard, N. B., Gasbjerg, L. S., Hansen, L. S., Hansen, N. L., Stensen, S., Hartmann, B., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Knop, Filip K
- ORCID
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03
- Volume
- 184
- Issue
- 3
- Pages
- 383-394
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W3119324073
- Cited by
- 37
- References
- 23
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 8 · 2023: 7 · 2022: 6 · 2021: 3
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Steno Diabetes Center Copenhagen (SDCC 3.F CMP)
- Novo Nordisk Fonden (NNF12OC1015904, NNF18SA0034956)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- acarbose, glucagon-like peptide-1, type 2 diabetes, postprandial blood glucose, alpha-glucosidase inhibitors, exendin-9-39, GLP-1 receptor, glucose tolerance, metformin, mixed meal tolerance test
- MeSH terms
- Aged, Aged, 80 and over, Blood Glucose, Denmark, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gastric Emptying, Humans, Insulin Resistance, Male, Metformin, Middle Aged, Placebos, Cross-Over Studies, Postprandial Period, Acarbose, Insulin-Secreting Cells, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. https://app.cochat.ai/papers/10.1530/eje-20-1121
- The paper
- Dalsgaard, N. B., Gasbjerg, L. S., Hansen, L. S., Hansen, N. L., Stensen, S., Hartmann, B., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021). The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. European Journal of Endocrinology. https://doi.org/10.1530/eje-20-1121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.